Baidu
map

呼吸指南

订阅

MedSci主页 / 所有栏目 / 呼吸指南

2018年GOLD慢性阻塞性肺疾病诊断、治疗及预防全球策略解读

2017-12-26 中国医学前沿杂志（电子版）.2017,9(12):15-22.

慢性阻塞性肺病COPD

慢性阻塞性肺疾病全球创议（global initiative for chronic obstructive lung disease，GOLD）2018年修订版于2017 年11 月15 日世界慢阻肺日发布，相对于GOLD 2017，该版内容并没有太大修改。 本文对于新增加的关于慢阻肺的危险因素、肺功能随访、急性加重频率的波动、药物治疗及非药物治疗等方面的内容进行简介和解读。

中文标题：

2018年GOLD慢性阻塞性肺疾病诊断、治疗及预防全球策略解读

发布机构：

发布日期：

2017-12-26

简要介绍：

慢性阻塞性肺疾病全球创议（global initiative for chronic obstructive lung disease，GOLD）2018年修订版于2017 年11 月15 日世界慢阻肺日发布，相对于GOLD 2017，该版内容并没有太大修改。

本文对于新增加的关于慢阻肺的危险因素、肺功能随访、急性加重频率的波动、药物治疗及非药物治疗等方面的内容进行简介和解读。

作者： 北京大学第三医院呼吸与危重症医学科 陈亚红

 

拓展指南：与慢性阻塞性肺疾病相关指南：

相关资料下载：
[AttachmentFileName(sort=100, fileName=2018年GOLD慢性阻塞性肺疾病诊断、治疗及预防全球策略解读)] GetToolGuiderByIdResponse(projectId=1, id=3d4661c00153ea58, title=2018年GOLD慢性阻塞性肺疾病诊断、治疗及预防全球策略解读, enTitle=, guiderFrom=中国医学前沿杂志（电子版）.2017,9(12):15-22., authorId=null, author=, summary=慢性阻塞性肺疾病全球创议（global initiative for chronic obstructive lung disease，GOLD）2018年修订版于2017 年11 月15 日世界慢阻肺日发布，相对于GOLD 2017，该版内容并没有太大修改。 本文对于新增加的关于慢阻肺的危险因素、肺功能随访、急性加重频率的波动、药物治疗及非药物治疗等方面的内容进行简介和解读。 , cover=, journalId=null, articlesId=null, associationId=null, associationName=, associationIntro=, copyright=0, guiderPublishedTime=Tue Dec 26 00:00:00 CST 2017, originalUrl=, linkOutUrl=, content=<P>慢性阻塞性肺疾病全球创议（global initiative for chronic obstructive lung disease，GOLD）2018年修订版于2017 年11 月15 日世界慢阻肺日发布，相对于GOLD 2017，该版内容并没有太大修改。 <BR><BR>本文对于新增加的关于慢阻肺的危险因素、肺功能随访、急性加重频率的波动、药物治疗及非药物治疗等方面的内容进行简介和解读。</P>作者： 北京大学第三医院呼吸与危重症医学科 陈亚红 <P> </P>拓展指南：<strong>与<font color=red>慢性阻塞性肺疾病</font>相关指南：</strong><br><ul><li><a href="//m.capotfarm.com/guideline/show_article.do?id=558721c0015201c6" title="2018 GOLD慢性阻塞性肺疾病全球倡议：COPD诊断、治疗与预防全球策略" target=_blank>2018 GOLD慢性阻塞性肺疾病全球倡议：COPD诊断、治疗与预防全球策略</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=413801c00151a8bb" title="慢性阻塞性肺疾病患者非肺部手术麻醉及围手术期管理专家共识" target=_blank>慢性阻塞性肺疾病患者非肺部手术麻醉及围手术期管理专家共识</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=019521c0015009da" title="慢性阻塞性肺疾病急性加重的治疗策略：2017欧洲呼吸学会/美国胸科学会指南解读" target=_blank>慢性阻塞性肺疾病急性加重的治疗策略：2017欧洲呼吸学会/美国胸科学会指南解读</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=4a80c1c001a90e38" title="2017 ERS/ATS慢性阻塞性肺疾病急性加重管理指南解读" target=_blank>2017 ERS/ATS慢性阻塞性肺疾病急性加重管理指南解读</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=8db3b1c001a022dd" title="2016年更新版GOLD慢性阻塞性肺疾病诊断、治疗和预防的全球策略简介（中文版）" target=_blank>2016年更新版GOLD慢性阻塞性肺疾病诊断、治疗和预防的全球策略简介（中文版）</a></li> 更多信息请点击：<a href="//m.capotfarm.com/guideline/list.do?q=%E6%85%A2%E6%80%A7%E9%98%BB%E5%A1%9E%E6%80%A7%E8%82%BA%E7%96%BE%E7%97%85" target=_blank>有关慢性阻塞性肺疾病更多指南</a></ul>, tagList=[TagDto(tagId=7070, tagName=慢性阻塞性肺病), TagDto(tagId=295, tagName=COPD)], categoryList=[CategoryDto(categoryId=12, categoryName=呼吸, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=解读, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=15554, appHits=1263, showAppHits=12, pcHits=11500, showPcHits=3953, likes=129, shares=47, comments=8, approvalStatus=1, publishedTime=Thu Dec 28 17:42:42 CST 2017, publishedTimeString=2017-12-26, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Thu Dec 28 17:42:42 CST 2017, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 00:15:04 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2018年GOLD慢性阻塞性肺疾病诊断、治疗及预防全球策略解读)])
2018年GOLD慢性阻塞性肺疾病诊断、治疗及预防全球策略解读
下载请点击：
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=907345, encodeId=e16890e3455b, content=特别受用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0fe5443590, createdName=ms5000002009642071, createdTime=Sat Dec 12 18:11:02 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307628, encodeId=f74a30e62846, content=十分受益.特别是里面很多临床研究的介绍给了自己一些启示, beContent=null, objectType=guider, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dfa2334195, createdName=122780e1m62暂无昵称, createdTime=Fri Apr 20 17:25:05 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274607, encodeId=a0e22e4607f6, content=学习了!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLF3V7KY7WyRVHCticgpdCWVsqAsLGF1UrrVc5TFS9ZI2DrEs5plCGBUaLqHXvCU4fhImjFdZ9PjiaS/0, createdBy=8f971728670, createdName=1dee1b88m43(暂无匿称), createdTime=Tue Jan 02 00:26:28 CST 2018, time=2018-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274533, encodeId=ffd42e4533bd, content=henhao, beContent=null, objectType=guider, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=b10c1938054, createdName=1e0e5697m83(暂无匿称), createdTime=Mon Jan 01 16:14:32 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274222, encodeId=4b3e2e422279, content=嗯嗯好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ab9d2220416, createdName=120fafe0m52暂无昵称, createdTime=Sun Dec 31 15:50:20 CST 2017, time=2017-12-31, status=1, ipAttribution=)]
    2020-12-12 ms5000002009642071

    特别受用

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=907345, encodeId=e16890e3455b, content=特别受用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0fe5443590, createdName=ms5000002009642071, createdTime=Sat Dec 12 18:11:02 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307628, encodeId=f74a30e62846, content=十分受益.特别是里面很多临床研究的介绍给了自己一些启示, beContent=null, objectType=guider, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dfa2334195, createdName=122780e1m62暂无昵称, createdTime=Fri Apr 20 17:25:05 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274607, encodeId=a0e22e4607f6, content=学习了!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLF3V7KY7WyRVHCticgpdCWVsqAsLGF1UrrVc5TFS9ZI2DrEs5plCGBUaLqHXvCU4fhImjFdZ9PjiaS/0, createdBy=8f971728670, createdName=1dee1b88m43(暂无匿称), createdTime=Tue Jan 02 00:26:28 CST 2018, time=2018-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274533, encodeId=ffd42e4533bd, content=henhao, beContent=null, objectType=guider, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=b10c1938054, createdName=1e0e5697m83(暂无匿称), createdTime=Mon Jan 01 16:14:32 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274222, encodeId=4b3e2e422279, content=嗯嗯好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ab9d2220416, createdName=120fafe0m52暂无昵称, createdTime=Sun Dec 31 15:50:20 CST 2017, time=2017-12-31, status=1, ipAttribution=)]
    2018-04-20 122780e1m62暂无昵称

    十分受益.特别是里面很多临床研究的介绍给了自己一些启示

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=907345, encodeId=e16890e3455b, content=特别受用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0fe5443590, createdName=ms5000002009642071, createdTime=Sat Dec 12 18:11:02 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307628, encodeId=f74a30e62846, content=十分受益.特别是里面很多临床研究的介绍给了自己一些启示, beContent=null, objectType=guider, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dfa2334195, createdName=122780e1m62暂无昵称, createdTime=Fri Apr 20 17:25:05 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274607, encodeId=a0e22e4607f6, content=学习了!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLF3V7KY7WyRVHCticgpdCWVsqAsLGF1UrrVc5TFS9ZI2DrEs5plCGBUaLqHXvCU4fhImjFdZ9PjiaS/0, createdBy=8f971728670, createdName=1dee1b88m43(暂无匿称), createdTime=Tue Jan 02 00:26:28 CST 2018, time=2018-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274533, encodeId=ffd42e4533bd, content=henhao, beContent=null, objectType=guider, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=b10c1938054, createdName=1e0e5697m83(暂无匿称), createdTime=Mon Jan 01 16:14:32 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274222, encodeId=4b3e2e422279, content=嗯嗯好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ab9d2220416, createdName=120fafe0m52暂无昵称, createdTime=Sun Dec 31 15:50:20 CST 2017, time=2017-12-31, status=1, ipAttribution=)]
    2018-01-02 1dee1b88m43(暂无匿称)

    学习了!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=907345, encodeId=e16890e3455b, content=特别受用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0fe5443590, createdName=ms5000002009642071, createdTime=Sat Dec 12 18:11:02 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307628, encodeId=f74a30e62846, content=十分受益.特别是里面很多临床研究的介绍给了自己一些启示, beContent=null, objectType=guider, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dfa2334195, createdName=122780e1m62暂无昵称, createdTime=Fri Apr 20 17:25:05 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274607, encodeId=a0e22e4607f6, content=学习了!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLF3V7KY7WyRVHCticgpdCWVsqAsLGF1UrrVc5TFS9ZI2DrEs5plCGBUaLqHXvCU4fhImjFdZ9PjiaS/0, createdBy=8f971728670, createdName=1dee1b88m43(暂无匿称), createdTime=Tue Jan 02 00:26:28 CST 2018, time=2018-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274533, encodeId=ffd42e4533bd, content=henhao, beContent=null, objectType=guider, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=b10c1938054, createdName=1e0e5697m83(暂无匿称), createdTime=Mon Jan 01 16:14:32 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274222, encodeId=4b3e2e422279, content=嗯嗯好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ab9d2220416, createdName=120fafe0m52暂无昵称, createdTime=Sun Dec 31 15:50:20 CST 2017, time=2017-12-31, status=1, ipAttribution=)]
    2018-01-01 1e0e5697m83(暂无匿称)

    henhao

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=907345, encodeId=e16890e3455b, content=特别受用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0fe5443590, createdName=ms5000002009642071, createdTime=Sat Dec 12 18:11:02 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307628, encodeId=f74a30e62846, content=十分受益.特别是里面很多临床研究的介绍给了自己一些启示, beContent=null, objectType=guider, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dfa2334195, createdName=122780e1m62暂无昵称, createdTime=Fri Apr 20 17:25:05 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274607, encodeId=a0e22e4607f6, content=学习了!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLF3V7KY7WyRVHCticgpdCWVsqAsLGF1UrrVc5TFS9ZI2DrEs5plCGBUaLqHXvCU4fhImjFdZ9PjiaS/0, createdBy=8f971728670, createdName=1dee1b88m43(暂无匿称), createdTime=Tue Jan 02 00:26:28 CST 2018, time=2018-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274533, encodeId=ffd42e4533bd, content=henhao, beContent=null, objectType=guider, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=b10c1938054, createdName=1e0e5697m83(暂无匿称), createdTime=Mon Jan 01 16:14:32 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274222, encodeId=4b3e2e422279, content=嗯嗯好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ab9d2220416, createdName=120fafe0m52暂无昵称, createdTime=Sun Dec 31 15:50:20 CST 2017, time=2017-12-31, status=1, ipAttribution=)]
    2017-12-31 120fafe0m52暂无昵称

    嗯嗯好

    0

相关指南

2018 GOLD慢性阻塞性肺疾病全球倡议：COPD诊断、治疗与预防全球策略

慢性阻塞性肺疾病全球倡议(GOLD,The Global Initiative for Chronic Obstructive Lung Disease) · 2017-11-01

2017 GOLD慢性阻塞性肺疾病全球倡议：COPD诊断、治疗与预防全球策略

暂未更新 · 2016-11-10

慢性阻塞性肺病全球倡议慢性阻塞性肺病 指南（2013更新版）解读

暂未更新 · 2016-04-20

Baidu
map
Baidu
map
Baidu
map